Keira Annie Markey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2105989/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurology, The, 2016, 15, 78-91.	10.2	321
2	ldiopathic intracranial hypertension: consensus guidelines on management. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1088-1100.	1.9	303
3	Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ: British Medical Journal, 2010, 341, c2701-c2701.	2.3	257
4	Diagnosis and management of migraine in ten steps. Nature Reviews Neurology, 2021, 17, 501-514.	10.1	194
5	Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 982-992.	1.9	173
6	11β-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews, 2013, 34, 525-555.	20.1	152
7	The expanding burden of idiopathic intracranial hypertension. Eye, 2019, 33, 478-485.	2.1	148
8	Migraine: disease characterisation, biomarkers, and precision medicine. Lancet, The, 2021, 397, 1496-1504.	13.7	141
9	European headache federation consensus on the definition of resistant and refractory migraine. Journal of Headache and Pain, 2020, 21, 76.	6.0	126
10	A randomised controlled trial of treatment for idiopathic intracranial hypertension. Journal of Neurology, 2011, 258, 874-881.	3.6	118
11	European Headache Federation guideline on idiopathic intracranial hypertension. Journal of Headache and Pain, 2018, 19, 93.	6.0	111
12	NMRâ€based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases – a diagnostic tool?. NMR in Biomedicine, 2010, 23, 123-132.	2.8	105
13	Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension. JAMA Neurology, 2021, 78, 678.	9.0	86
14	Cerebrospinal Fluid Corticosteroid Levels and Cortisol Metabolism in Patients with Idiopathic Intracranial Hypertension: A Link between 11β-HSD1 and Intracranial Pressure Regulation?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5348-5356.	3.6	84
15	Rating papilloedema: an evaluation of the Frisén classification in idiopathic intracranial hypertension. Journal of Neurology, 2012, 259, 1406-1412.	3.6	83
16	Headache determines quality of life in idiopathic intracranial hypertension. Journal of Headache and Pain, 2015, 16, 521.	6.0	79
17	Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom. JAMA Neurology, 2019, 76, 1088.	9.0	79
18	Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention. Journal of Neuro-Ophthalmology, 2018, 38, 522-530.	0.8	78

KEIRA ANNIE MARKEY

#	Article	IF	CITATIONS
19	Exploring the pathogenesis of IIH: An inflammatory perspective. Journal of Neuroimmunology, 2008, 201-202, 212-220.	2.3	74
20	A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Science Translational Medicine, 2017, 9, .	12.4	71
21	Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol. BMJ Open, 2017, 7, e017426.	1.9	63
22	Advances in the understanding of headache in idiopathic intracranial hypertension. Current Opinion in Neurology, 2019, 32, 92-98.	3.6	61
23	Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment. Lancet Neurology, The, 2021, 20, 460-469.	10.2	56
24	A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight, 2019, 4, .	5.0	55
25	Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: Minimal gain, is it worth the pain?. Cephalalgia, 2019, 39, 245-253.	3.9	51
26	What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open, 2019, 9, e026573.	1.9	48
27	11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Communications, 2020, 2, fcz050.	3.3	46
28	Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight, 2021, 6, .	5.0	45
29	Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension. JAMA Ophthalmology, 2020, 138, 1264.	2.5	43
30	11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 174-187.	3.6	39
31	Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. Journal of Headache and Pain, 2021, 22, 39.	6.0	39
32	Evaluation and management of adult idiopathic intracranial hypertension. Practical Neurology, 2018, 18, 485-488.	1.1	38
33	The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension. Neurology: Clinical Practice, 2021, 11, e504-e507.	1.6	38
34	Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey. BMJ Open, 2018, 8, e020445.	1.9	37
35	Headache attributed to idiopathic intracranial hypertension and persistent postâ€idiopathic intracranial hypertension headache: A narrative review. Headache, 2021, 61, 808-816.	3.9	37
36	Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial. JMIR Research Protocols, 2017, 6, e181.	1.0	33

KEIRA ANNIE MARKEY

#	Article	IF	CITATIONS
37	Erenumab for headaches in idiopathic intracranial hypertension: A prospective openâ€ l abel evaluation. Headache, 2021, 61, 157-169.	3.9	31
38	Idiopathic intracranial hypertension: Update on diagnosis and management. Clinical Medicine, 2020, 20, 384-388.	1.9	29
39	Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 795-797.	1.9	28
40	Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension. Current Opinion in Neurology, 2019, 32, 422-431.	3.6	27
41	Emerging themes in idiopathic intracranial hypertension. Journal of Neurology, 2020, 267, 3776-3784.	3.6	27
42	Should we educate about the risks of medication overuse headache?. Journal of Headache and Pain, 2014, 15, 10.	6.0	26
43	Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure. Brain Communications, 2021, 3, fcab202.	3.3	26
44	Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. Journal of Headache and Pain, 2020, 21, 116.	6.0	24
45	New horizons for idiopathic intracranial hypertension: advances and challenges. British Medical Bulletin, 2020, 136, 118-126.	6.9	23
46	Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT). Journal of Neurology, 2022, 269, 1945-1956.	3.6	17
47	Managing idiopathic intracranial hypertension in pregnancy: practical advice. Practical Neurology, 2022, 22, 295-300.	1.1	17
48	Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 2019-2027.	2.3	17
49	Migraine, cerebrovascular disease and the metabolic syndrome. Annals of Indian Academy of Neurology, 2012, 15, 72.	0.5	16
50	Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension: evidence from a single-payer healthcare system. Surgery for Obesity and Related Diseases, 2021, 17, 1310-1316.	1.2	15
51	The Role of Metabolism in Migraine Pathophysiology and Susceptibility. Life, 2021, 11, 415.	2.4	14
52	Outcomes measures in idiopathic intracranial hypertension. Expert Review of Neurotherapeutics, 2021, 21, 687-700.	2.8	12
53	Disability from posttraumatic headache is compounded by coexisting posttraumatic stress disorder. Journal of Pain Research, 2017, Volume 10, 1991-1996.	2.0	11
54	Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension. European Journal of Endocrinology, 2022, 187, 323-333.	3.7	11

#	Article	IF	CITATIONS
55	Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. Eye, 2020, 34, 1321-1333.	2.1	9
56	Cerebrospinal fluid shunting protocol for idiopathic intracranial hypertension for an improved revision rate. Journal of Neurosurgery, 2022, 136, 1790-1795.	1.6	8
57	Tip of the iceberg in idiopathic intracranial hypertension. Practical Neurology, 2019, 19, 178-179.	1.1	5
58	CHARACTERISING FAT DISTRIBUTION AND RESPONSE TO WEIGHT LOSS IN IIH. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.208-e1.	1.9	0
59	WED 097â€Diagnostic lumbar punctures in IIH: what is the patient experience?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A10.2-A10.	1.9	0
60	United Kingdom CSF Disorders Day 2018. Neuro-Ophthalmology, 2019, 43, 131-134.	1.0	0